arterial blood News
-
Study Finds MediPines’ Breakthrough Non-invasive Gas Exchange Method Highly Precise: Ideal for Covid Response
A recent clinical study published by medical researchers from UC San Diego School of Medicine has established that an expired breath sampling method is comparable to the long-established blood-based method (ABG) of measuring pulmonary gas exchange efficiency. Published in the American Journal of Physiology Lung Cellular and Molecular Physiology, the study, entitled “Measuring the ...
By MediPines
-
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval TSC was safe and well-tolerated by all subjects with no serious adverse events reported Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) ...
By CervoMed
-
Revolutionising Cardiovascular Health: Monitoring the Surface Metallurgy of Stents
In a ground-breaking advancement for cardiovascular care, Hiden Analytical Ltd is proud to announce a surface measurement technique for devices critical in the treatment of heart disease. Utilizing the most sensitive surface analysis technology, Secondary Ion Mass Spectrometry (SIMS), Hiden Analytical is setting new standards in the safety, efficacy, and innovation of stent technology. Surgical ...
-
1 out of 10 survive cardiac arrest, a new device under FDA review hopes to change that
KEY POINTS Cardiac arrest is one of the leading causes of death in the U.S. and globally. It has a survival rate of 1 in 10 people with current treatment. The Neurescue device is designed to increase blood flow to the brain and heart during life-threatening emergencies such as cardiac arrest. Cardiac arrest is one of the leading causes of death around the world, ...
By Neurescue
-
Ground-breaking New Medical Device Saving Lives and Resources During Pandemic
A ground-breaking development in the detection of reduced lung function, as seen in COVID-19 patients, is saving lives, time, and resources. It’s thanks to the world’s first non-invasive lung function monitor, the MediPines AGM100®, developed in California, tested at University of British Columbia and Stevenson Memorial Hospital, and approved for use in Canada. Hospitals are ...
By MediPines
-
Air pollution from road traffic can raise blood pressure
High blood pressure is linked to long-term exposure to traffic-related air pollution, new research suggests. After accounting for lifestyle factors, socioeconomic status and pre-existing health conditions, the researchers found that a rise in traffic emissions of nitrogen dioxide corresponded to a rise in blood pressure of exposed individuals. Long-term exposure to air pollution has previously ...
-
Saneron and Henry Ford Health: Cell Therapy Combo Aids Stroke
Researchers at the Henry Ford Health System (Detroit, MI) and colleagues at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, have found that when human umbilical cord blood cells (HUCBCs) were transplanted into test rats modeled with stroke, the addition of Simvastatin to the HUCBCs significantly increased the therapeutic benefit of the HUCBCs. The study was published in a recent issue of ...
-
MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.
Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The ...
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
Showcase
Wired: This startup wants to stop deaths from cardiac arrest?
In April 2013, final-year Danish medical student Habib Frost was called out to an emergency: a four-month old girl had just suffered cardiac arrest. Frost’s team tried defibrillation, but to no avail. Immediately after, the team was called out again: another case of cardiac arrest, this time a woman in her 30s. Once again, Frost was powerless to save her life. “I felt ...
By Neurescue
-
FDA Clears Rex Medical Bioresorbable Vascular Closure Device
August 3, 2016 — The U.S. Food and Drug Administration (FDA) has granted market clearance to Rex Medical’s bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations. The vascular closure device consists of an insertion sheath, dilator and an implant contained in a delivery system. It uses a patch placed against the artery wall ...
-
Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation
The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with peripheral artery disease (PAD) after revascularization. The approval is based on data from the Phase III VOYAGER PAD trial. This study demonstrated a positive ...
By Bayer AG
-
Robocath successfully completes first robotic coronary angioplasties in Belgium
Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional ...
By Robocath
-
World Thrombosis Day
On World Thrombosis Day, October 13, 2021, Emosis is proud to be a "messenger" of the "Eyes open to Thrombosis" information campaign. Eyes open to Thrombosis WTD is an educational campaign to raise awareness and educate the public to the importance of reducing death and disability from thrombosis. It is a global alliance of thousands of local, regional, national and international ...
-
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson
Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson. The collaboration will bring the global resources and know-how of the largest and most respected healthcare ...
-
ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS
MILPITAS, Calif. – January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The results were presented at the 30th Annual Live Interventions in Vascular Endotherapy ...
-
SKI Vascular Center is First Ambulatory Surgical Center in the Nation to Utilize FDA-Approved Ellipsys System for Non-Surgical Dialysis Fistula Creation
Tempe-based interventional nephrologists Randy Cooper, MD and Umar Waheed, MD, and their team at SKI Vascular Center, this week became the first ambulatory surgical center in the US to create a percutaneous arteriovenous fistula (AVF), using the Ellipsys® Vascular Access System, a game-changing innovation for patients with End-Stage Renal Disease (ESRD). The recently FDA-approved Ellipsys ...
-
Diesel Exhaust + Cholesterol = Cardiovascular Disease
LOS ANGELES, California, July 26, 2007 (ENS) - Exposure to a combination of diesel exhaust and high blood cholesterol increases the risk for heart attack and stroke far more than exposure to either factor alone, new research reveals. The results indicate that controlling air pollution may prove to be a powerful tool for preventing cardiovascular disease. Published in today's edition of the ...
-
First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid disease, including patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR), will be presented at the upcoming Society for ...
-
Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open. The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you